- Home
- MNOV vs WEA Comparison
MNOV vs WEA Comparison
Compare MNOV & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNOV | WEA |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 125.4M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNOV | WEA |
|---|---|---|
| Price | $2.64 | $9.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 683.6K | 43.3K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $180.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $9.87 |
| 52 Week High | $3.90 | $11.42 |
Technical Indicators
Market Signals| Indicator | MNOV | WEA |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 28.87 |
| Support Level | $1.28 | N/A |
| Resistance Level | $3.90 | $10.72 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 43.06 | 12.90 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The fund invests in bonds of companies operating in different sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.